The webinar will be held in a hybrid delivery format (on-site and online).
In Europe, testing for thermogenic substances using rabbits will be banned starting in 2026.
We have developed “Mylc MAT” as an alternative method for animal testing.
This webinar will introduce the benefits of “Mylc MAT” and the movement toward the revision of the Pharmacopoeia.
We also invite you to join us for a tour of our laboratory to see how “Mylc MAT” is being implemented.
Date: Thursday, August 24, 2023, 17:00-18:00 (including Q&A session)
Location: Innovation Park, Creative Lab for Innovation in Kobe 2nd floor and
Zoom (participation URL will be sent the day before to those who have registered)
Monocyte Activation Test (MAT), not just an alternative to animal testing
Pyrogen test is mandatory for pharmaceutical products and vaccines to confirm that they are not contaminated with microorganism-derived pyrogenic substances. The laws of each country require that this test be conducted for each lot prior to shipment.
Until now, tests using animals (resources) such as rabbits have been the mainstream, but the European Pharmacopoeia Commission has announced a plan to ban animal testing for thermogenic substances in July 2026. The European Pharmacopoeia now includes a monocyte activation test (MAT) using human monocyte cells as an alternative to animal testing, and this trend is expected to spread worldwide in the future.
We have the core technology to provide human myeloid cells, which play an important role in infectious diseases and immune system disorders, “in large quantities, stably, and continuously”. We have developed “Mylc Cells” by utilizing this technology. This time, we prepared Mylc cells for MAT from cells with good reactivity to microorganisms and started to provide them for testing as “MylcMAT”.
It is expected that MAT will be replaced by MAT not only from the perspective of animal welfare, but also as a safety assessment for various modalities including regenerative medicine products. In this seminar, we will introduce the benefits of introducing MAT and the movement toward the next revision of the Japanese Pharmacopoeia. We also invite you to a tour of our laboratory, where you can see how “MylcMAT” is being implemented.
MiCAN Technologies Inc. 2nd Webinar (Hybrid: Free of Charge)
~Monocyte Activation Test (MAT) – not just an alternative to animal testing~
Lecturer: Kazuo Miyazaki, CEO, MiCAN Technologies, Inc.
Date: Thursday, August 24, 2023, 17:00-18:00 (including Q&A)
・How and where to participate:
Zoom Webinar (participation URL will be sent the day before to those who have registered)
or
Innovation Park, Creative Lab for Innovation in Kobe 2nd floor
6-3-7 Minatojima-minamimachi, Chuo-ku, Kobe-shi, Hyogo
（https://www.kups.jp/clik/park.html）
Please register using the registration form below.
To ensure that the webinar is meaningful to you, please complete the pre-survey when you register.
Acceptance of applications has been closed.
